Mesoblast Ltd ADRMSB
Price$14.32

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $17.2M+191.4% YoYTTM through 31 Dec 2025
Net Income -$102.1MTTM through 31 Dec 2025
Free Cash Flow -$50.6MTTM through 31 Dec 2025

Margins

Current
Net Margin-593.9%

Returns

-17.8%ROE
-13.1%ROA

Balance Sheet Health

Debt / Equity0.10x
Current Ratio1.58x
Net Debt-$69.8Mnet cash position
Cash & Equivalents$130M

Quality Metrics

Piotroski F-Score3 / 9
FCF Margin-294.4%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $17.2M
Diluted EPS
'19'20'21'22'23'24'25
FY2025: $-0.08

Dividend

No dividend

Capital Allocation

Capex Intensity4.0%

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.